


wherein

*Handwritten: A2 cont.*

R<sub>1</sub> is selected from the group consisting of hydrogen, carbobenzyloxy-, carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-alanine-asparagine-, carbobenzyloxy-threonine-valine- and carbobenzyloxy-valine-valine-;


R<sub>2</sub> is selected from the group consisting of -CH<sub>2</sub>-Phenyl, and -CH<sub>2</sub>-CH(CH<sub>3</sub>)<sub>2</sub>;

R<sub>3</sub> is a radical represented by the formula:




wherein R<sub>4</sub> is a radical selected from the group consisting of -(H)<sub>2</sub>, and -H(t-Butyl).

7. A protease inhibitor according to claim 6 represented by the following structure:



8. A protease inhibitor according to Claim 1 represented by the following structure:




wherein

R<sub>1</sub> is selected from the group consisting of carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-alanine-asparagine-, carbobenzyloxy-threonine-valine- and carbobenzyloxy-valine-valine-;


R<sub>2</sub> is selected from the group consisting of -CH<sub>2</sub>-Phenyl, and -CH<sub>2</sub>-CH(CH<sub>3</sub>)<sub>2</sub>;

R<sub>3</sub> is a radical represented by the formula:




wherein R<sub>4</sub> is a radical selected from the group consisting of -(H)<sub>2</sub>, and -H(t-Butyl).

9. A protease inhibitor according to claim 8 represented by the following structure:




10. A protease inhibitor according to Claim 2 represented by the following structure:




wherein  $R_1$  is a radical selected from the group consisting of carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-alanine-asparagine- and carbobenzyloxy-valine-valine-;  $R_2$  is selected from the group consisting of  $-CH_2-Phenyl$ , and  $-CH_2-CH(CH_3)_2$ .


11. A protease inhibitor according to claim 10 represented by the following structure:




12. A protease inhibitor according to claim 10 represented by the following structure:




13. A protease inhibitor according to claim 10 represented by the following structure:




14. A protease inhibitor according to claim 10 represented by the following structure:




15. A protease inhibitor according to claim 10 represented by the following structure:




16. A protease inhibitor according to claim 10 represented by the following structure:




17. A protease inhibitor according to claim 10 represented by the following structure:



18. A protease inhibitor according to claim 3 represented by the following structure:



19. A protease inhibitor according to Claim 4 represented by the following structure:



wherein  $R_1$  is a radical selected from the group consisting of carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-valine-valine- and carbobenzyloxy-alanine-asparagine-.

20. A protease inhibitor according to claim 19 represented by the following structure:

